Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study

被引：165

作者：

Guignard, S. ^{[1
]}

Gossec, L. ^{[1
]}

Salliot, C. ^{[1
]}

Ruyssen-Witrand, A. ^{[1
]}

Luc, M. ^{[1
]}

Duclos, M. ^{[1
]}

Dougados, M. ^{[1
]}

机构：

[1] Univ Paris 05, Fac Med, APHP, Cochin Hosp,Rheumatol Dept B, F-72019 Paris, France

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2006年 / 65卷 / 12期

关键词：

D O I：

10.1136/ard.2006.052092

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: To evaluate the efficacy of anti-tumour necrosis factor (TNF) treatments (given for rheumatological manifestations) in reducing uveitis flares in patients with spondylarthropathy in daily practice. Methods: A retrospective observational study of all patients with spondylarthropathy with at least one uveitis flare treated with anti-TNF in one centre (December 1997 -December 2004). The number of uveitis flares per 100 patient-years was compared before and during anti-TNF treatment; each patient was his or her own control. The relative risk (RR) and the number needed to treat (NNT) were calculated. Results: 46 patients with spondylarthropathy treated with anti-TNF drugs had at least one uveitis flare (33 treated with anti-TNF antibodies, infliximab or adalimumab, and 13 with soluble TNF receptor, etanercept). The mean age at first symptoms was 26 years, 71% were men. Patients were followed for 15.2 years (mean) before anti-TNF versus 1.2 years during anti-TNF treatment. The number of uveitis flares per 100 patient-years before and during anti-TNF were, respectively: for all anti-TNF treatments, 51.8 v 21.4 (p = 0.03), RR = 2.4, NNT= 3 (95% confidence interval (CI = 2 to 5); for soluble TNF receptor 54.6 v 58.5 (p = 0.92), RR = 0.9; and for anti-TNF antibodies -50.6 v 6.8 (p = 0.001), RR = 7.4, NNT= 2 (95% CI = 2 to 5). Conclusion: Anti-TNF treatments were efficacious in decreasing the number of uveitis flares in patients with spondylarthropathy. Anti-TNF antibodies decreased the rate of uveitis flares, whereas soluble TNF receptor did not seem to decrease this rate. These results could have consequences for the choice of anti-TNF treatment in certain patients.

引用

页码：1631 / 1634

页数：4

共 15 条

[11]

Oh J, 2005, J RHEUMATOL, V32, P752

[12] Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab [J].

Papadakis, KA ;

Shaye, OA ;

Vasiliauskas, EA ;

Ippoliti, A ;

Dubinsky, MC ;

Birt, J ;

Paavola, J ;

Lee, SK ;

Price, J ;

Targan, SR ;

Abreu, MT .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (01) :75-79

[13]

Sands Bruce E, 2004, Rev Gastroenterol Disord, V4 Suppl 3, pS10

[14] TNFα inhibitors in the treatment of psoriasis and psoriatic arthritis [J].

Tobin, AM ;

Kirby, B .

BIODRUGS, 2005, 19 (01) :47-57

[15] Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease [J].

Van Den Brande, JMH ;

Braat, H ;

Van Den Brink, GR ;

Versteeg, HH ;

Bauer, CA ;

Hoedemaeker, I ;

Van Montfrans, C ;

Hommes, DW ;

Peppelenbosch, MP ;

Van Deventer, SJH .

GASTROENTEROLOGY, 2003, 124 (07) :1774-1785

← 1 2 →